New EU fees would cancel promised savings, says pharma association

02/24/2014 | FDAnews

New industry fees to cover the costs of postmarket reviews of drug safety, which could run as high as $330,000 per drug, would wipe out savings to pharmaceutical firms promised in the 2010 pharmacovigilance law, the European Federation of Pharmaceutical Industries and Associations says. The EFPIA called on EU officials to provide greater transparency of such oversight costs. The European Parliament and the Council of the European Union must approve the fees.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI